Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease

Abstract

Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) is a new type of anti-diabetes drug. Clinical studies have shown that SGLT-2i plays a beneficial role in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). SGLT-2i can reduce hepatic endoplasmic reticulum stress, regulate inflammatory reaction, improve liver fibrosis and increase hepatocyte autophagy to alleviate symptoms of NAFLD patients.

Keywords

• non-alcoholic fatty liver disease|sodium-glucose cotransporter 2 inhibitor